CapitalBio Technology

About CapitalBio Technology

CapitalBio Technology Inc., founded in August 2012, operates as the core industrialization platform for CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips. The company has its origins in Tsinghua University, where its founder, Dr. Cheng Jing, began developing China's biochip technology, or "China Chip," in 1999 as part of the university's "Hundred Talents Program." Dr. Cheng, a Chinese Academy of Engineering academician, leveraged his background in engineering and molecular biology, including his work on creating the world's first "1 square centimeter ultra-micro laboratory" in 1998, to establish the company. His vision was to create affordable, locally-focused products to solve real-world health problems.

The firm focuses on developing and commercializing biochip-related technologies, offering a comprehensive suite of products and services for life science research and clinical diagnostics. Its business model integrates research and development, production, sales, and third-party independent medical laboratory services. CapitalBio Technology generates revenue by providing instruments, equipment, supporting reagents, and consumables to a diverse client base that includes domestic and international markets in scientific research, clinical diagnostics, inspection and quarantine, and agriculture. The company has established a robust technology system centered around biochips, sequencing, multiplex PCR, and mass spectrometry.

CapitalBio's product portfolio is extensive, featuring molecular detection products for hereditary diseases, infectious diseases, and tumors. A significant offering is their microarray platform, which includes diagnostic chips for various diseases, gene expression profiling arrays, and genotyping services. The company has developed notable products such as a deafness gene mutation detection kit, a joint detection product for the early detection of liver cancer, and a respiratory pathogens nucleic acid detection kit that was approved for emergency use during the COVID-19 pandemic. Additionally, they offer a range of instruments like microarray scanners, hybridization stations, and the BioelectronSeq 4000 Sequencer, which utilizes semiconductor sequencing technology for clinical laboratories. The company also provides sequencing services, including whole-genome, transcriptome, and single-cell sequencing.